These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 22177244)

  • 21. Spectrum of neuroendocrine carcinomas of the uterine cervix, including histopathologic features, terminology, immunohistochemical profile, and clinical outcomes in a series of 50 cases from a single institution in India.
    Rekhi B; Patil B; Deodhar KK; Maheshwari A; A Kerkar R; Gupta S; Tongaonkar HB; Shrivastava SK
    Ann Diagn Pathol; 2013 Feb; 17(1):1-9. PubMed ID: 22534245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Breast cancer in the elderly: a histological assessment.
    Tse GM; Tan PH; Lau KM; de Andrade VP; Lui PC; Vong JS; Chaiwun B; Lam CC; Yu AM; Moriya T
    Histopathology; 2009 Oct; 55(4):441-51. PubMed ID: 19817895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
    Wang-Rodriguez J; Cross K; Gallagher S; Djahanban M; Armstrong JM; Wiedner N; Shapiro DH
    Mod Pathol; 2002 Aug; 15(8):853-61. PubMed ID: 12181271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Male breast cancer: immunohistochemical subtypes and clinical outcome characterization.
    Sánchez-Muñoz A; Román-Jobacho A; Pérez-Villa L; Sánchez-Rovira P; Miramón J; Pérez D; Sáez MI; de Luque V; Medina L; Ramírez-Tortosa CL; Vicioso L; Medina JA; Ribelles N; Alba E
    Oncology; 2012; 83(4):228-33. PubMed ID: 22907070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Primary neuroendocrine tumors of the breast: a retrospective study of 21 cases and literature review].
    Feki J; Fourati N; Mnif H; Khabir A; Toumi N; Khanfir A; Boudawara T; Amouri H; Daoud J; Frikha M
    Cancer Radiother; 2015 Aug; 19(5):308-12. PubMed ID: 26215367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
    Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
    Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroendocrine carcinomas of the uterine cervix: A clinicopathological study.
    Sitthinamsuwan P; Angkathunyakul N; Chuangsuwanich T; Inthasorn P
    J Med Assoc Thai; 2013 Jan; 96(1):83-90. PubMed ID: 23720983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Invasive micropapillary carcinoma of the breast: clinicopathologic study of 62 cases of a poorly recognized variant with highly aggressive behavior.
    Pettinato G; Manivel CJ; Panico L; Sparano L; Petrella G
    Am J Clin Pathol; 2004 Jun; 121(6):857-66. PubMed ID: 15198358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM; Zhang BN; Xuan LX; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
    Nassar A; Sussman ZM; Lawson D; Cohen C
    Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
    Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
    Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Morphological features of basal-like subtype invasive carcinoma of breast].
    Gao LX; Yang GZ; Ding HY; Li L
    Zhonghua Bing Li Xue Za Zhi; 2008 Feb; 37(2):83-7. PubMed ID: 18681317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. INSM1 is a novel prognostic neuroendocrine marker for luminal B breast cancer.
    Razvi H; Tsang JY; Poon IK; Chan SK; Cheung SY; Shea KH; Tse GM
    Pathology; 2021 Feb; 53(2):170-178. PubMed ID: 32951906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroendocrine differentiation in breast cancer: established facts and unresolved problems.
    Righi L; Sapino A; Marchiò C; Papotti M; Bussolati G
    Semin Diagn Pathol; 2010 Feb; 27(1):69-76. PubMed ID: 20306832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gastric neuroendocrine carcinoma: clinicopathologic review and immunohistochemical study of E-cadherin and Ki-67 as prognostic markers.
    Boo YJ; Park SS; Kim JH; Mok YJ; Kim SJ; Kim CS
    J Surg Oncol; 2007 Feb; 95(2):110-7. PubMed ID: 17066436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular subtyping of male breast cancer by immunohistochemistry.
    Kornegoor R; Verschuur-Maes AH; Buerger H; Hogenes MC; de Bruin PC; Oudejans JJ; van der Groep P; Hinrichs B; van Diest PJ
    Mod Pathol; 2012 Mar; 25(3):398-404. PubMed ID: 22056953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. E-cadherin expression in molecular types of breast carcinoma.
    Ionescu Popescu C; Giuşcă SE; Liliac L; Avadanei R; Ceauşu R; Cîmpean AM; Balan R; Amălinei C; Ciobanu Apostol D; Căruntu ID
    Rom J Morphol Embryol; 2013; 54(2):267-73. PubMed ID: 23771069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both?
    Raica M; Cîmpean AM; Ceausu RA; Fulga V; Nica C; Rudico L; Saptefrati L
    Anticancer Res; 2014 Mar; 34(3):1435-40. PubMed ID: 24596391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.